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1  | INTRODUCTION
The	 treatment	 paradigm	 for	 patients	 with	 decompensated	 hepatitis	
C	(HCV)	cirrhosis	has	changed	dramatically	after	the	introduction	of	the	











be	 initiated	 if	 patients	 have	 sufficient	 time	 to	 achieve	undetectable	
HCV-	RNA	before	LT,	but	the	timing	to	transplantation	is	often	unpre-





ment	 of	 liver	 function	 in	 many	 patients,	 thus	 reducing	 waiting-	list	
mortality	 and	 even	 leading	 to	 inactivation	 and	withdrawal	 from	 the	
transplant	 list	 in	 some	 cases.8,9	However,	 if	 liver	 function	 improves	
during	treatment	but	does	not	eliminate	the	need	for	LT,	these	patients	
are	at	disadvantage	for	graft	allocation	when	the	system	is	based	only	




Unfortunately,	 clinical	 evidences	 in	 the	pretransplant	 setting	are	
quite	limited.	In	the	pivotal	study	by	Curry	et	al10	including	waitlisted	
patients	 with	 Child-	Pugh	 score	 ≤B7	 and	 hepatocellular	 carcinoma	
(HCC),	the	combination	of	sofosbuvir	plus	ribavirin	(SOF/R)	prevented	
HCV	 recurrence	 in	 96%	 of	 patients	with	 undetectable	 viraemia	 for	
at	least	4	weeks	before	LT,	but	only	in	36%	with	undetectable	virae-
mia	for	less	than	4	weeks.	De-	listing	was	reported	in	18%	of	patients	
waiting	 for	 LT	 after	 treatment	with	 SOF-	based	 regimes	 in	 a	 French	
multicentre	 cohort.9	 More	 recently,	 a	 retrospective	 analysis	 of	 103	










2  | PATIENTS AND METHODS














function	 in	 about	 half	 of	 patients	 awaiting	 liver	
transplantation.






















min,	 according	 with	 the	 SOF	 Summary	 of	 Product	 Characteristics,	
pregnant/nursing	women,	 and	 history	 of	 significant	 drug	 allergy	 to	
	nucleoside/nucleotide	analogues.
The	 study	 conforms	 to	 the	 ethical	 guidelines	 of	 the	 1975	
Declaration	 of	 Helsinki	 and	 all	 patients	 gave	 their	 written	 consent	


























tive	 variables.	 For	 continuous	 variables	 normality	 of	 distribution	 and	
homogeneity	of	variances	were	assessed	by	the	Kolmogorov–Smirnov	

















in	 the	 Italian	 transplant	centres	 received	SOF/R	within	 the	national	
ITACOPS	program.	As	shown	 in	Figure	1,	of	 these	243	patients,	19	
(7.8%)	were	excluded	by	the	present	analysis	because	the	data	were	






























22	 (9.8%)	 patients	 were	 also	 treated	 with	 a	 second	 DAA	 obtained	
through	a	company-	driven	compassionate	program	(18	patients	with	





































Finally,	 48	 patients	 stopped	 therapy	 at	 LT	 being	 the	 HCV-	RNA	
undetectable	for	more	than	4	weeks	with	an	SVR12	of	88%	(42/48).
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MELD	 decreased	 in	 45%	 of	 cases,	 increased	 in	 33%	 and	 remained	
stable	in	22%	(P	=	.292),	while	Child-	Pugh	decreased	in	53%	of	cases,	
















disease,	 the	 probability	 was	 significantly	 higher	 for	 both	 prognostic	
scores,	being	around	35%	after	24	weeks	and	65%	after	48	weeks	for	
MELD	and	50%	after	24	weeks	and	60%	after	48	weeks	for	Child-	Pugh.
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thus	with	a	clear	indication	to	OLT	based	on	clinical	liver	decompen-
sation	(Figure	3A).	We	also	decided	to	consider	patients	as	potential	
candidates	 for	 inactivation	 and	 delisting	when	 they	 reached	 a	 con-
dition	defined	by	Child-	Pugh	class	A	 invariably	 associated	 to	MELD	
score	<15.
During	 the	 entire	 period	 of	 observation	 of	 60	weeks,	 36	 pa-
tients	 were	 transplanted	 and	 2	 died	 for	 complications	 of	 liver	
disease.	We	 also	 excluded	 five	 patients	 with	 a	 follow-	up	 shorter	
than	 24	weeks.	Of	 the	 remaining	 47	 patients	 (median	 follow-	up:	
48	weeks	 [min/max:	24-	60]),	 15	became	Child-	Pugh	class	A	asso-
ciated	 to	 a	MELD	 score	<15	at	 the	 last	 available	 follow-	up.	Thus,	
17.4%	 of	 patients	 presented	 clinical	 scores	 suitable	 for	 inactiva-
tion	 and	 then	 delisting	 (Figure	3B).	 Figure	3C	 shows	 changes	 of	
the	 MELD	 and	 Child-	Pugh	 scores	 observed	 in	 these	 15	 patients	
from	baseline	to	the	last	visit	available	(median	follow-	up:	56	weeks	
[min/max:	 24-	60]).	 Interestingly,	 the	 pre-	treatment	 highest	MELD	
was	22	and	Child-	Pugh	was	C10.
To	identify	predictors	of	inactivation,	we	compared	at	the	univar-





static	 factors,	 predictors	 of	 inactivation	were	 baseline	 lower	 Child-	
Pugh	 score	 and	 absence	of	HE,	while	 the	Delta	MELD	 score,	Delta	
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4  | DISCUSSION










et	al10	 showed	 that	 antiviral	 treatment	 can	effectively	prevent	HCV	
recurrence	 only	 if	 the	 patients	 have	 undetectable	 HCV-	RNA	 for	 at	
least	30	days	before	LT.	However,	these	data	were	confined	to	Child	
A	 patients	with	 HCC.	 Two	 novel	 data	 emerge	 from	 the	 analysis	 of	
our	patients	who	were	 transplanted	and	achieved	an	overall	SVR12	
















than	 those	observed	 in	decompensated	 cirrhosis.1,2,15	However,	 it	
can	also	occur	that	patients	in	stable	conditions,	for	whom	the	full	




viral	 clearance	 for	 at	 least	 30	days,	 the	 recommendations	 of	 the	
European	Liver	and	Intestine	Transplant	Association	(ELITA),	based	
on	 the	 expert	 opinion,	 state	 that	 bridging	 therapy	 can	 be	 consid-













results	 emerged	 from	 this	 analysis:	 first,	 the	 probability	was	 signifi-
cantly	higher	in	patients	with	a	more	advanced	disease;	second,	about	
half	of	patients	present	a	decrease	of	their	scores	of	such	an	extent	
which	may	be	of	 clinical	 relevance;	 and	 third,	 the	 improvement	 be-
comes	manifest	 already	 few	weeks	 after	 the	 initiation	of	 therapy	 in	
some	patients	and	occurs	within	24	weeks	in	most	of	them.
If	obtaining	a	clinical	improvement	or	even	blocking	the	progres-
sion	of	 the	disease	obviously	 represents	a	goal	of	 therapy	 in	all	pa-
tients	with	decompensated	cirrhosis	who	do	not	have	 indication	for	
LT,	 this	may	be	not	the	case	of	waitlisted	patients	as	the	MELD	 im-
provement	 can	 also	 reduce	 the	priority	 for	 LT	 in	 the	 centres	where	
organ	 allocation	 is	 based	 on	 disease	 severity	 (the	 so	 called	 “MELD	
purgatory”).	Thus,	 in	 this	 specific	 setting,	 a	 critical	 issue	 appears	 to	
determine	which	patients	 can	be	 inactivated	and	 then	delisted	as	 a	
result	of	viral	eradication.


















Beside	 a	 baseline	 lower	 Child-	Pugh	 score	 and	 less	 HE	 preva-
lence,	patients	who	reached	the	condition	suitable	for	 inactivation	
had	 a	 significantly	 greater	 improvement	 of	 MELD	 scores	 and	 its	
components	as	well	as	of	serum	albumin	after	4	weeks	of	therapy	
compared	 to	 those	who	 did	 not.	As	 a	 result,	 the	 delta	MELD	be-
tween	0	and	4	weeks	was	found	able	to	stratify	patients	for	achiev-
ing	 a	 condition	 of	 potential	 inactivation	 with	 a	 probability	 after	
48	weeks	 of	 about	 20%	 if	MELD	 after	 4	weeks	 increased,	 50%	 if	
MELD	remained	stable	or	decreased	1	point,	and	65%	if	decreased	
of	 at	 least	 2	points.	Taken	 together,	 these	data	 suggest	 that	 non-	






in	almost	90%	of	 the	 recipients	provided	 that	bridging	 therapy	 is	per-
formed	in	those	patients	still	viraemic	or	negative	for	less	than	4	weeks	
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at	 transplantation.	 Furthermore,	 viral	 eradication	 is	 associated	 to	 an	 
improvement	of	liver	function	in	more	than	half	of	the	cases,	which	can	
reach	a	 condition	of	 inactivation	and	 then	de-	listing	 in	almost	20%	of	
non-	HCC	 patients	 including	 some	with	 a	 severely	 compromised	 liver	
function.
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